Drug Profile
VX 10367
Latest Information Update: 07 May 2003
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical; Vertex Pharmaceuticals
- Class Antihyperglycaemics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 07 May 2003 Discontinued - Preclinical for Type-1 diabetes mellitus (unspecified route)
- 01 Apr 1997 No-Development-Reported for Type-1 diabetes mellitus (Unknown route)
- 14 Oct 1994 Preclinical development for Type-1 diabetes mellitus (Unknown route)